Product Program year 2025 Source: CMS Open Payments

Cysview

Drug Oncology

NDC 10511-3001-2

Open in the dashboard

General payments

$1,051,735

4,211 payments

Research payments

$988,800

188 payments

Through program year 2025, $1,051,735 in general payments and $988,800 in research payments were reported against Cysview (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

10 rows
Year Kind Amount Payments
2025 General $92,896 756
2025 Research $455,473 85
2024 General $179,408 741
2024 Research $301,957 67
2023 General $222,265 640
2023 Research $231,370 36
2022 General $158,906 551
2021 General $132,313 427
2020 General $99,324 267
2019 General $166,623 829

Breakdown

Who paid General payments · program years 2019–2025
  1. Photocure Inc $1,051,735 4,211 payments
Top recipients General payments · program year 2025
  1. Siamak Daneshmand Urology · Los Angeles, CA $17,139 18% · 2 payments
  2. Vignesh Packiam Urology · Iowa City, IA $15,037 16% · 12 payments
  3. Gautam Jayram Urology · Nashville, TN $11,132 12% · 4 payments
  4. Gary Steinberg Urology · Chicago, IL $3,199 3% · 2 payments
  5. Tara Cumming Nurse Practitioner, Acute Care · San Antonio, TX $2,730 3% · 3 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Urology $75,841 89% · 410 practitioners
  2. Nurse Practitioner, Acute Care Nurse Practitioner $3,045 4% · 9 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $1,569 2% · 49 practitioners
  4. Nurse Practitioner $1,096 1% · 26 practitioners
  5. Physician Assistant $871 1% · 37 practitioners

The top 5 of 23 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $22,835 25% · 52 recipients
  2. Tennessee $16,838 18% · 66 recipients
  3. Iowa $15,179 16% · 2 recipients
  4. Michigan $5,139 6% · 61 recipients
  5. Texas $4,734 5% · 9 recipients

The top 5 of 39 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Cysview
Billing code Providers Services Paid by Medicare
Instillation, hexaminolevulinate hydrochloride, 100 mg A9589 4 92 $95,649

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

4,211 general · 188 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record